The quest for a single-pill once-a-day treatment for HIV became a reality when the FDA approved Atripla on July 12. It combines the already approved drugs efavirenz (Sustiva), tenofovir (Viread), and ...
Black gay men face major PrEP access gaps due to cost, stigma, mistrust, and provider silence—despite high HIV impact; ...
Advocacy groups from 30 countries are urging Merck to create a global access strategy for its once-a-month HIV prevention ...
The approval could slow new infections and move the world closer to eliminating HIV. But huge obstacles remain.
"The future looks bright as far as a cure," one top HIV cure researcher told LGBTQ Nation.
Observers are calling proposed changes to state-funded HIV assistance its biggest rollback since the aid went into place.